At Aescap we invest in highly innovative medical biotech companies. This is reflected in our name, which is derived from Aesculapius, the Roman god of medicine and Capital. Aescap began investing in the Life Science industry when the company started its first fund, Aescap 1, back in 2006. Ten years later we started our second fund Aescap 2.0.
Aescap 2.0 was launched late March 2016. This open-end fund invests in innovative medical companies listed on a stock exchange. It invests especially in those companies which are on the forefront of innovation, often around biotechnology, and develop new medicines and to a lesser extent diagnostics and/or medical devices. Aescap 2.0 has a focused portfolio, investing in approximately 15-20 companies. Within this focus it will ensure that the portfolio is diversified over different diseases, development phases and geographies. The Fund’s objective is to make an average minimum annual net return (after deduction of costs) of 20%+ over the mid-term (4 years).
Fund manager Patrick Krol has more than 30 years of experience in the healthcare industry. He developed an investment strategy based on his own experiences over many years as an investor in private as well as public medical companies. Over the last four years, 2014-2017, Patrick realised a performance of 170% and with that outperformed the Nasdaq Biotech Index (NBI) by 75%.
The fund and participant administration and supervision of the fund manager is outsourced to the renowned trust office SGG Group. Investors can step in and out of the fund on a monthly basis. The minimal investor’s investment amount is € 0.5 million. If you would like to receive more information, you can request a prospectus or send an email to email@example.com.